Latest in Type 2 Diabetes

tigersroar.com
167 words

Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase II Study in Participants with Diabetes

- ASC30 reduced HbA1c by a placebo-adjusted 1.7%, 1.6% and 1.7% from baseline for 40 mg, 60 mg and 80 mg, respectively, at 12 weeks, the primary endpoint. - ASC30 achieved placebo-adjusted weight reduction of 4.4%, 3.8% and 4.0% from baseline for 40 mg, 60 mg and 80 mg, respectively and no plateau was observed, at 13 weeks, a…

finance.yahoo.com
234 words

New Data Presented at Diabetes Technology Society Meeting Support Safe Intravenous Insulin Dosing During Labor and Delivery with EndoTool IV

Real-world analysis of 267 patients showed tight glycemic control and no severe hypoglycemia events highlighting the potential for technology-enabled glycemic management across labor and delivery The poster, "Use of a Computerized Intravenous Insulin Dosing Application in Pregnancy," evaluated outcomes among patients…

Type 2 Diabetes

Type 2 diabetes: diagnosis, treatment and new drugs, and remission through diet and weight loss.

  • 5 Tracked terms
  • Last 30 days Feed window

What this topic collects on

An article joins this feed when it matches these terms. Each one is also a search of its own.